You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
環亞國際醫療集團(01143.HK)擬對南京濟朗進行戰略投資
格隆匯 04-21 21:36

格隆匯4月21日丨環亞國際醫療集團(01143.HK)發佈公吿,於2021年4月21日,公司透過全資子公司,環亞醫療科技投資有限公司,與南京濟朗生物科技有限公司及朱書漢先生訂立戰略投資備忘錄。

根據備忘錄,環亞投資擬對南京濟朗進行戰略投資,持有南京濟朗約15%的股份。自備忘錄簽訂日期起計90日內,公司將對南京濟朗進行盡職調查。待盡職調查完成且公司認為滿意後,環亞投資將與南京濟朗簽署正式的投資協議。

南京濟朗,是於中國註冊成立的有限責任公司,主要從事女性生殖健康相關的早期生物診斷技術研究。南京濟朗聚焦於生殖健康系列化無創快速監測和體外診斷產品的開發,其擁有女性黃體功能快速無創監測技術專利,其核心產品女性激素無創快速檢測(PdG)試劑盒即將完成臨牀實驗。南京濟朗的性激素無創監測技術填補了國內女性生殖健康無創監測細分領域中的空白,且能實現從備孕、孕前診斷到孕後監控整個過程的動態監測,可以滿足國內不孕不育、輔助生殖、優生優育女性人羣的龐大需求。

董事會認為,南京濟朗的性激素無創監測技術具有創新性,可廣泛應用於排卵期預測、不孕症中的激素診斷檢測、早期胎兒健康監測等方向,方便不孕不育、優生優育女性動態檢測、監控激素水平,提升備孕、助孕的成功率。如果本次戰略投資能夠實現,將拓寬集團在輔助生殖醫療科技產業鏈的佈局,豐富相關的技術儲備,為集團輔助生殖服務業務的發展帶來協同效應。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account